Pfizer to buy Hospira for about $15 billion

(Reuters) - Drugmaker Pfizer Inc said it would buy Hospira Inc for about $15 billion to gain access to its biosimilars. The offer of $90 per share represents a premium of 39 percent to Hospira stock's close on Wednesday. The total enterprise value of the deal is about $17 billion, the companies said. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)

via Health News Headlines - Yahoo News Read More Here..